All Content Outsourced Pharma

  1. Minaris Advanced Testing Capabilities Update March 2026: Analytical Services 3/24/2026

    Access integrated biosafety testing, viral clearance, product characterization, and GMP analytics that deliver regulatory‑ready data and speed biologic and cell and gene therapy development.

  2. Fuji Pharma And Gedeon Richter Conclude Agreement For Joint Development Projects In Women's Health 3/24/2026

    Fuji Pharma Co., Ltd. (Headquarters: Chiyoda‑ku, Tokyo; hereinafter “Fuji Pharma”) announces that, in relation to the strategic collaboration with Gedeon Richter Plc. (Headquarters: Hungary; hereinafter “Richter”) disclosed on February 3, 2026, the two companies have entered into and signed an agreement regarding the joint development of multiple product candidates in the field of women’s health.

  3. Applied StemCell And Cellipont Bioservices Partner To Offer A Seamless Path For iPSC-Derived Cell Therapy Development 3/24/2026

    Applied StemCell, Inc. (“ASC”), a genome engineering company with deep expertise in induced pluripotent stem cell (iPSC) technology and Cellipont Bioservices, a cell therapy contract development and manufacturing organization (CDMO), today announced a strategic collaboration designed to streamline and accelerate the development of iPSC-derived cell therapies.

  4. Yatiri Bio Enters Exclusive Option To In-License Agreement With Oscotec For Denfivontinib In AML 3/24/2026

    Yatiri Bio, Inc., a leader in AI-driven precision medicine, today announced it has entered into an exclusive global option to license agreement with Oscotec, Inc. to develop and commercialize denfivontinib (SKI-G-801), a potent multikinase inhibitor, for the treatment of Acute Myeloid Leukemia (AML).

  5. SK pharmteco And Prozomix Announce Strategic Collaboration To Enhance Biocatalysis Capabilities For Global Drug Manufacturing 3/24/2026

     SK pharmteco, a leading global contract development and manufacturing organization (CDMO), and Prozomix, a pioneer in enzyme discovery and diversity, today announced a strategic partnership.

  6. Stability Issues Unique To Liquid Injectables And How To Avoid Them 3/23/2026

    Liquid injectables face stability risks like oxidation, hydrolysis, aggregation, temperature shifts, and packaging effects, requiring early, rigorous formulation and process controls.

  7. Lentitek And ViroCell Announce Commercial Collaboration 3/23/2026

    As cell and gene therapies move toward increasingly complex genetic payloads, manufacturing challenges are emerging as a key bottleneck in the development of the next-generation of therapies.

  8. What If The U.S. Government Stopped Funding Biotech? 3/23/2026

    It sets off a real tension – ideological, economic, even personal. But what would happen if the U.S. government cut direct financial support for “biotechnology research,” leaving it entirely to investors, private and public markets, and bigger pharma? "Our industry’s mind-meld says with no government largesse our biotech industry collapses," writes Chief Editor Louis Garguilo. It's an "outlandish hypothetical," but he asks for a few minutes to go through this. And he has help in making his case.

  9. Cytiva And Yoshindo Advance Domestic Biosimilar Manufacturing In Japan Through FlexFactory Collaboration 3/23/2026

    Cytiva, a Danaher company and a leader in the life sciences industry, today announced that it has signed a FlexFactory contract with Yoshindo, supporting the company’s plans to establish domestic biosimilar drug substances manufacturing capabilities for the Japanese market.

  10. Lifecore Biomedical Signs Commercial Site Transfer Agreement With Leading Medical Aesthetics Company 3/23/2026

    Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it has signed a CDMO manufacturing services agreement with a new aesthetics customer for an established, market-approved product.